Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Epilepsia. Author manuscript; available in PMC 2009 September 11.
Published in final edited form as:
PMCID: PMC2742493

Growing old with epilepsy

The neglected issue of cognitive and brain health in aging and elder persons with chronic epilepsy


The purpose of this review is to examine what is known about cognitive and brain aging in elders with chronic epilepsy. We contend that much remains to be learned about the ultimate course of cognition and brain structure in persons with chronic epilepsy and concern appears warranted. Individuals with chronic epilepsy are exposed to many risk factors demonstrated to be associated with abnormal cognitive and brain aging in the general population, with many of these risk factors present in persons with chronic epilepsy as early as midlife. We suggest that a research agenda be developed to systematically identify and treat known modifiable risk factors in order to protect and promote cognitive and brain health in aging and elder persons with chronic epilepsy.

Keywords: Aging, Cognition, Chronic epilepsy, Risk factors

Although epilepsy is a prevalent neurological disorder with known cognitive consequences, in the review to follow we will contend that the course of cognition and brain structure in aging (age 50+) and elder (age 65+) persons with chronic epilepsy is very poorly understood. Virtually no literature addresses this important issue, but we will present data to suggest that there are several reasons for concern. Numerous cognitive deficits, neuroimaging abnormalities, and psychiatric comorbidities have been well characterized in younger persons with chronic epilepsy, with evidence of progression of these problems in some patients by middle age. In that context, people with chronic epilepsy have been exposed to several factors that may place them at increased risk for accelerated cognitive and brain aging, including treatment with medications now known to adversely affect cholesterol, folate and glucose metabolism; increased rates of vascular disease risk factors; altered lifestyles that include decreased social interaction and physical inactivity; and elevated inflammatory markers. In the general aging literature, prospective studies have confirmed the association of these factors with abnormal cognitive and brain aging as well as the risk of dementia including vascular dementia (VaD) and Alzheimer’s disease (AD). We will argue that for aging and elder persons with chronic epilepsy these risk factors have never been comprehensively characterized, never thoroughly examined in relation to major dimensions of physical health (e.g., vascular, pulmonary, cerebral blood flow), and never directly related to cognitive function or brain structure.

At the present time, unprecedented efforts are under way to understand the causes of abnormal cognitive and brain aging in the general population, but similar research in epilepsy is virtually nonexistent. For persons with chronic epilepsy, little is known about the impact of aging on the course of cognitive and brain health, the prevalence of clinical disorders of aging (mild cognitive impairment, dementia), or the disease burdens and modifiable risk factors associated with abnormal cognitive and brain aging. In the material to follow we will review existing studies to address these points. While recent attention regarding epilepsy in aging individuals has centered on elders with new-onset epilepsy (Collins et al., 2006; Cloyd et al., 2006), the focus here is on persons who have lived with epilepsy for long periods of time (15+ years) and are now middle-aged and older.

Chronic Epilepsy is a Prevalent Disorder That May be Associated with Significant Abnormalities in Cognition, Brain Structure, and Psychiatric Health That Progress in Some Patients by Middle Age

An extensive body of cross-sectional neuropsychological research documents impairments in general intellectual ability (IQ) and specific cognitive functions (e.g., memory) in persons with chronic epilepsy and the association of these impairments with disease variables such as early age of onset and seizure frequency (Jones-Gotman, 2000; Aldenkamp & Arends, 2004; Elger et al., 2004). A long-standing concern has been whether chronic pharmacoresistent epilepsy causes progressive cognitive decline over time (Helmstaedter & Elger, 1999; Jokeit & Ebner, 1999; Pitkanen & Sutula, 2002). The number of controlled prospective investigations is modest but the findings suggest progressive cognitive impairment in a subset of patients (cf, Helmstaedter et al., 2003; Dodrill, 2004; Seidenberg et al., in press). Our own controlled prospective cohort study documented an abnormal cognitive trajectory, including memory, among patients with chronic temporal lobe epilepsy compared to healthy controls, a trajectory that was associated with chronicity of disorder. The extent of abnormality was poorly predicted by traditional specific disease-related factors (e.g., seizure frequency), suggesting that other important causes are involved and remain to be identified (Hermann et al., 2006). Importantly, these individuals were middle-aged at follow-up (mean age approximately 40) and yet to face the effects of normal aging on cognition and brain structure, cognitive changes (Dixon et al., 2004) that will be superimposed on an already compromised substrate.

Similarly, a growing neuroimaging literature, best characterized in patients with chronic temporal lobe epilepsy, has demonstrated distributed abnormalities in the hippocampus, temporal and extratemporal regions (e.g., frontal lobe, cerebellum), and subcortical structures (e.g., caudate, thalamus), as well as reduction in cerebral white matter and thinning of the cortical mantle with abnormal gyral/sulcal curvature, with reported progression of some of these abnormalities in a subset of patients (Sisodiya et al., 1997; Sandok et al., 2000; Liu et al., 2001, 2003; Duncan, 2002; Keller et al., 2002; Hermann et al., 2003, 2004; Bernasconi et al., 2004; McMillan et al., 2004; Oyegbile et al., 2004; Bonilha et al., 2006; Lin et al., 2007; Pulsipher et al., in press; Yu et al., in press). Not only are some of these volumetric abnormalities associated with cognitive status in cross-sectional research (Trenerry et al., 1995; Baxendale et al., 1998; Martin et al., 1999; Sawrie et al., 2001; Pegna et al., 2002; Alessio et al., 2004; Bonilha et al., In press), but volumetric abnormalities have also been found to be predictive of adverse cognitive change in short-term (4-year) prospective studies of middle-aged patients with chronic epilepsy (e.g., Hermann et al., 2006).

Brain imaging studies of normal aging have revealed age-related reductions in cerebral blood flow and cerebral metabolic rate of oxygen consumption (Pantano et al., 1984), glucose metabolism in the frontal and temporal lobes (De Santi et al., 1995), white matter integrity measured using diffusion tensor imaging (DTI) (Ardekani et al., 2007; Malloy et al., 2007), and volume reductions in distributed brain regions including medial temporal lobes and prefrontal cortex (Raz et al., 2007). Recent evidence from functional MRI studies suggest that increasing age is also associated with changes in brain activity across the lifespan on several tasks including both episodic and working memory paradigms (Persson & Nyberg, 2006). Among patients with chronic epilepsy, these normal age related changes may then be superimposed on an already adversely affected neural substrate as summarized above. To date there is no information addressing the course and ultimate status of brain structure in aging and elder persons with chronic epilepsy.

Psychiatric comorbidites are overrepresented in the epilepsies (Jones et al., 2005; Swinkels et al., 2005; Tellez-Zenteno et al., in press). There has been little investigation of the natural history and risk of progression of these disorders in medically managed patients with chronic epilepsy. Recent evidence has documented higher prospective rates of DSM-IV Axis I disorders and especially mood disorders in persons with chronic temporal lobe epilepsy compared to controls, even after adjustment for prior psychiatric history (Jones et al., in press). We are not aware of any data addressing the psychiatric status of elders with chronic epilepsy.

The findings reviewed above raise concern regarding the risk for abnormal/accelerated cognitive, brain, and psychiatric aging in elder persons with chronic epilepsy. At this time of major interest and investigation of cognitive and brain aging in the general population, there has been no systematic investigation of cognition, brain structure, or psychiatric health in aging persons and elders with chronic epilepsy, a significant oversight given the accumulating evidence of risk factor exposure in this population. In addition, other evidence potentially suggestive of an increased risk for abnormal cognitive and brain aging comes from other sources in the epilepsy literature and it is to those factors that we now turn.

Potential Risk Factors for Abnormal Cognitive and Brain Aging in Epilepsy and Mental Status in Elders with Epilepsy

Neuropathological studies in temporal lobe epilepsy, mental status screening in elders with established epilepsy, and studies of association between epilepsy and cognitive disorders in elders with epilepsy raise concern regarding cognitive and brain aging in persons with chronic epilepsy.

Up-regulated amyloid precursor protein, senile plaque deposition, and corpora amylacea in chronic epilepsy

Examining brain tissue from middle-aged patients with epilepsy undergoing anterior temporal lobectomy (n = 8), immunoreactive β-amyloid precursor protein levels were found to be higher compared to age-matched postmortem controls (n = 8) (Sheng et al., 1994). Mackenzie and Miller (1994) examined Aβ deposition in resected human temporal lobe cortex obtained during anterior temporal lobectomy (n = 101) compared to autopsy controls (n = 406). Senile plaques were found in 10% of epilepsy patients, some of whom were aged <40, with a reported age-accelerated rate of senile plaque formation compared to controls that was especially prominent in the presence of the epsilon4 (e4) allele (Gouras et al., 1997), a known susceptibility factor for AD. Premature accumulation of corpora amylacea in middle age patients with mesial temporal lobe epilepsy has been reported (34.5% of 373 patients) and noted to be associated with older age and longer duration of epilepsy (Radhakrishnan et al., 2007). Whether these neuropathologies are associated with age-accelerated cognitive changes and risk of dementia in aging persons and elders with chronic epilepsy remains to be determined.

Abnormal cognition in elders with chronic epilepsy

We are aware of only four published studies that have directly assessed cognitive status in elders with chronic epilepsy (Martin et al., 2005; Griffith et al., 2006, 2007; Piazzini et al., 2006). Compared to healthy controls (n = 27), community-dwelling elders with chronic partial epilepsy (n = 25) exhibited significantly poorer performance across all scales of a dementia screening test (Dementia Rating Scale) (Martin et al., 2005). A related investigation (Griffith et al., 2006) compared matched groups of community-dwelling elders with chronic partial epilepsy (n = 26), healthy control elders (n = 26) and healthy elders with amnestic mild cognitive impairment, a known precursor to AD (n = 26). Compared to patients with amnestic MCI, community-dwelling elders with epilepsy exhibited a comparable degree of memory impairment and even greater impairment in executive function than this clinical group (Griffith et al., 2006), with significant worsening of the deficit in executive function in prospective follow-up of elders with chronic epilepsy (Griffith et al., 2007).

Association between epilepsy and dementia

Two population-based investigations of medical comorbidities (U.K., Canada) demonstrate a significantly higher association between dementia and AD in persons with epilepsy compared to controls (Gaitatzis et al., 2004; Tellez-Zenteno et al., 2005). It is widely appreciated that seizures are part of the natural history of AD. Population-based studies demonstrate that unprovoked seizures occur with increased incidence in persons with AD compared to nondemented elderly controls (Hauser et al., 1986; Romanelli et al., 1990; Hesdorffer et al., 1996; Amatniek et al., 2006). However, less appreciated is evidence suggesting that dementia may develop with greater frequency in aging and elder persons with chronic and established epilepsy compared to controls. Breteler et al. (1991), in the EURODEM project, reanalyzed eight case-control studies and reported that the risk for AD was significantly elevated in persons with established epilepsy (duration ≥10 years). In a later study, Breteler et al. (1995) demonstrated an age-accelerated risk of dementia in 4,505 persons with epilepsy, aged 50-75, compared to age-matched persons with other medical disorders over an 8-year observation period.

In addition to this evidence from the field of epilepsy, there is a large general population literature that has identified risk factors for abnormal cognitive and brain aging and it is to that literature that we now turn. Numerous risk factors for abnormal cognitive aging and dementia have been identified in prospective population-based research. Many of these factors are overrepresented in epilepsy but their relationships to cognitive and brain aging have never been examined.

Prospective research in nonepilepsy populations has identified a variety of risk factors associated with accelerated cognitive and brain aging and dementia including AD. In the material to follow, prospective data from community- and population-based cohort studies will be reviewed to characterize three classes of risk factors (vascular disease, inflammatory markers, and lifestyle factors) for dementia, followed by review of evidence demonstrating that these risk factors appear to be elevated in persons with chronic epilepsy, but never related to cognition in epilepsy.

Vascular disease risk factors

Hypertension (Knopman et al., 2001), hyperhomocysteinemia (Troen & Rosenberg, 2005), abnormal glucose metabolism (Greenwood & Winocur, 2005; Watson & Craft, 2006), hypercholesterolemia (Solfrizzi et al., 2006), and obesity/metabolic syndrome (Cournot et al., 2006; Gustafson, 2006) have been demonstrated in prospective investigations to be predictive of cognitive decline and dementia including VaD and AD in the general population. An emerging view is that vascular risk factors and vascular disease are responsible for accelerated cognitive and brain aging in the general population and may even represent a fundamental factor in provoking the neurodegenerative processes of AD (de la Torre, 2002, 2004, 2005). One of these risk factors, elevated plasma homocysteine, is associated with increased risk of heart disease, stroke, cerebrovascular disease and peripheral vascular disease (Clarke et al., 1991, 1998; Eikelboom et al., 1999; Hankey & Eikelboom, 1999; Wald et al., 2002; Refsum et al., 2006), and prospective research has demonstrated its association with cognitive decline (McCaddon et al., 2001; Dufouil et al., 2003) and dementia (Seshadri et al., 2002; Luchsinger et al., 2004; Ravaglia et al., 2005). Vascular risk factors contribute to atherosclerotic progression and endothelial dysfunction, key factors in the maintenance of cerebral blood flow, but also adversely affecting Aβ metabolism (Sparks et al., 1994; Fewlass et al., 2004).

Persons with chronic epilepsy may be at increased risk of abnormal cognitive and brain aging because of an increased prevalence of vascular risk factors that may result at least in part from treatment with antiepilepsy drugs (AEDs). Valproic acid (VPA) treatment has been associated with several metabolic disorders including hyperinsulinemia and insulin resistance (Isojarvi et al., 1998; Luef et al., 2004) and substantial weight gain/increased body mass index (BMI) (Pylvanen et al., 2003; Sheth, 2004). In addition to alterations in insulin sensitivity and body mass, commonly prescribed enzyme inducing medications (e.g., phenytoin [PHT], carbamazepine [CBZ]) disturb folate metabolism leading to significantly increased levels of homocysteine (Ono et al., 1997; Schwaninger et al., 1999; Yoo & Hong, 1999; Apeland et al., 2000; 2001a, b; Tamura et al., 2000; Verrotti et al., 2000; Tümer et al., 2002; Karabiber et al., 2003; Attilakos et al., 2006). Especially troubling are reports of elevated insulin resistance and hyperhomocysteinemia in children with epilepsy caused by AEDs (Verrotti et al., 2000; Tümer et al., 2002; Karabiber et al. 2003; Attilakos et al., 2006) since early exposure to vascular risk factors predict cerebrovascular disease in adults in the general population (Berenson et al., 1998; Berenson, 2002; Berenson & Srnivasan, 2005). Adults with chronic epilepsy have been found to have significantly increased carotid artery intima media thickness (IMT) (Schwaninger et al., 2000; Hamed et al., 2007) and early death from ischemic heart disease has been reported (Annegers et al., 1984). Population-based surveys of medical comorbidities document higher rates of hypertension, ischemic heart disease, heart failure, diabetes, and cerebrovascular disease in persons with epilepsy (Gaitatzis et al., 2004; Tellez-Zenteno et al., 2005). Prospective studies are needed to characterize directions of causality in these comorbidity studies as well as the specific relationships between abnormalities in cognitive and brain health that may be associated with these medical comorbidities in aging and elder persons with chronic epilepsy.

Epidemiological, clinical, and experimental investigations demonstrate that serum lipids and apolipoproteins are intimately related to atherosclerotic cardiovascular and cerebrovascular disease, cognitive disorder and dementia (Castro-Gago et al., 2006; Panza et al., 2006). In chronic epilepsy, AED-induced abnormalities in cholesterol and lipoprotein homeostasis have been reported. Reliable findings include (1) increased risk of dyslipidemia with enzyme-inducing medications, including CBZ, PHY, PB leading to elevations of total cholesterol and triglicerides (Hamed & Nabeshima, 2005), and (2) elevation of lipoprotein (a) in chronically treated children (Aynaci et al., 2001; Tümer et al. 2002; Sonmez et al. 2006; Voudris et al., 2006) and adults with epilepsy (Schwaninger et al., 2000; Voudris et al., 2006) as well as healthy volunteers exposed to AEDs (Brämswig et al., 2003). These disruptions in lipid and lipoprotein metabolism have been demonstrated in both cross-sectional and longitudinal epilepsy investigations. These important potentially modifiable vascular disease risk factors are elevated in persons with chronic epilepsy but have never been examined in relation to cognitive and brain aging.

Two examples of the possible significance of these factors for cognitive and brain aging will be briefly presented.

Carotid artery intima media thickness

Hamed et al. (2007) examined carotid artery intima media thickness (CIMT), vascular risk biomarkers, and oxidative stress in 225 adult epilepsy patients and 60 controls with a mean age of 30. Compared to controls, for epilepsy subjects the IMT of common carotid artery, bifurcation, and internal carotid arteries, respectively, was thickened in 51.1%, 73.3%, and 43.6% of epilepsy patients. Furthermore, a significantly greater proportion of epilepsy patients (14.2%) were found to have plaques compared to controls (2%). The majority of epilepsy patients (80%) had multiple risk factors, including significantly lower levels of high-density lipoprotein cholesterol, and significantly higher levels of homocysteine, fibrinogen, and von Willbrand factor. That “subclinical” atherosclerosis can have important long-term implications has been reported recently by the Rotterdam group. Following 6,647 participants, van Oijen et al. (2007) reported that atherosclerosis, predominantly carotid atherosclerosis, was associated with an increased risk of dementia. Critically, the relationship of atherosclerosis and its complications (e.g., decreased brain perfusion) to cognitive and brain change and dementia has been demonstrated in the general population, but never investigated in chronic epilepsy.

APOE epsilon4

Previous research has documented that epilepsy patients do not show an increased rate of the e4 allele (Kilpatrick et al., 1996; Gambardella et al., 1999; Cavalleri et al., 2005; Yeni et al., 2005) and there is no reliable relationship between the e4 allele and clinical seizure features (onset age, seizure frequency) (Kilpatrick et al., 1996; Blumcke et al., 1997; Gambardella et al., 1999; Briellmann et al., 2000; Cavalleri et al., 2005; Sporis et al., 2005; Yeni et al., 2005) with the exception of Diaz-Arrastia et al. (2003), who reported increased relative risk of late posttraumatic seizures with e4 allele. There is, however, evidence of age-accelerated senile plaque formation in chronic temporal lobe epilepsy (Gouras et al., 1997) and cross-sectional evidence of age-accelerated memory impairment in persons with chronic temporal lobe epilepsy in the presence of e4 (Gambardella et al., 2005; Busch et al., 2007).


Increasing evidence suggests that inflammation plays an integral role in the pathogenesis of cognitive decline and dementing disorders including AD (Dik et al., 2005). High-sensitivity C-reactive protein (hs-CRP) is an indicator of systemic inflammation and a novel plasma marker for atherosclerosis (Kuo et al., 2005). Five of six prospective community-based investigations showed elevated hs-CRP to be associated with cognitive decline and increased risk for dementia (Schmidt et al., 2002; Teunissen et al., 2003; Yaffe et al., 2003; Engelhart et al., 2004; Tilvis et al., 2004; Dik et al., 2005). Other markers of chronic inflammation include interleukin-6 (IL-6) and fibrinogen. IL-6 predicted cognitive decline in four of five prospective investigations (Weaver et al., 2002; Yaffe et al., 2003; Engelhart et al., 2004; Rafnsson et al., 2007, but not Dik et al., 2005), and fibrinogen predicted 4-year cognitive decline in the Edinbergh Artery Study (Rafnsson et al., 2007). Overall, prospective studies suggest that inflammatory markers (hs-CRP, IL-6, fibrinogen) are important predictors of adverse cognitive outcomes and recent reports link inflammatory biomarkers to age-accelerated cerebral atrophy as well (Jefferson et al., 2007).

Chronic epilepsy appears associated with an increased risk of exposure to inflammatory risk factors linked with abnormal cognitive aging and dementia. Evidence that persons with epilepsy may be particularly vulnerable to inflammation comes from both human and animal studies. For example, experimentally induced seizures trigger a prominent inflammatory response in neural areas involved in the onset and propagation of seizures (Vezzani, 2005; Vezzani & Granata, 2005). Increased inflammatory markers have been detected in serum, CSF, and brain in persons with epilepsy. Pertinent are findings of increased IL-6 following recent tonic-clonic seizures (Peltola et al., 2002; Lehtimaki et al., 2004). IL-6 has also been reported to be elevated secondary to CBZ but not VPA treatment (Verrotti et al., 2001) and elevated levels of fibrinogen have been reported in chronic epilepsy (Hamed et al., 2007). These important serum inflammatory markers that may be elevated in persons with chronic epilepsy have never been examined in relation to cognitive and brain aging.

Lifestyle factors

Lifestyle factors are associated with the risk of cognitive decline and dementia in the general population. Fratiglioni et al. (2004) reviewed 28 community-based prospective studies examining relationships between extent of social networks, physical activity, and leisure-time mental stimulation with the risk of cognitive decline, dementia, and AD. Evidence that lifestyle factors may influence cognitive aging is persuasive. In regard to the risk of prospective cognitive decline, 18 of 22 studies reported positive relationships. Specifically, seven of eight prospective investigations demonstrated a significant association between physical activity and cognitive health, six of seven prospective studies showed increased mental activity to be associated with preservation of cognitive health, and five of seven prospective studies demonstrated that the range and frequency of interaction with social networks were associated with better cognitive function.

Chronic epilepsy is associated with an increased prevalence of lifestyle factors associated with abnormal cognitive aging and dementia. Compared to healthy controls, epilepsy patients are less likely to participate in regular physical exercise/activity (Nakken, 1999; Wong & Wirrell, 2006) and demonstrate poorer aerobic capacity and diminished muscle strength and endurance (Bjorholt et al., 1990; Steinhoff et al., 1996; Jalava & Sillanpää, 1997). These lifestyle differences probably contribute to reports of elevated BMI in both adults (Steinhoff et al., 1996) and children (Wong & Wirrell, 2006). Persons with epilepsy have also been shown to have decreased contacts with available social networks (Bjorholt et al., 1990; Steinhoff et al., 1996), consistent with the known psychosocial consequences and felt stigma associated with epilepsy (Jacoby et al., 2005). These important potentially modifiable lifestyle risk factors are elevated in persons with chronic epilepsy but have never been examined in relation to cognitive and brain aging.

Vascular, lifestyle, inflammatory, and cognitive abnormalities in midlife are critical predictors of eventual cognitive and brain aging. A important body of research in the general population with direct implications for cognitive and brain aging in these individuals demonstrates that the presence of midlife risk factors including vascular (hypertension, dyslipidemia, obesity, diabetes mellitus), health habits (smoking, diet, physical activity), inflammatory markers (hs-CRP), and pulmonary function (forced expiratory volume) predict (1) the adequacy of late-life cognition; (2) the risk of developing mild cognitive impairment, dementia, and AD; (3) brain atrophy; and (4) the degree of neuropathological abnormalities at autopsy (Chyou et al., 1996; Launer et al., 2000; Petrovitch et al. 2000; Kivipelto et al., 2001a, b, 2002, 2005; Schmidt et al., 2002; Tyas et al., 2003; Rovio et al., 2005; Whitmer et al., 2005; Gustafson, 2006; Laitinen et al., 2006). In addition, midlife cognitive and especially memory impairments have prognostic significance for compromised mental status in later life (Zonderman et al., 1995; Kawas et al., 2003). The relationship between cognitive and brain health with vascular, lifestyle, and inflammatory risk factors is an important issue for people with epilepsy of any age, presenting an opportunity for early intervention and treatment. However, the long-term implications of these findings for cognitive and brain aging in there individuals must not be underestimated since increased exposure to these risk factors in midlife may be common for persons with chronic epilepsy. Because chronic epilepsy may be associated with progression of preexisting impairments in memory and other cognitive abilities as well as significant abnormalities in brain structure in midlife, there is a compelling argument to not only carefully examine the ultimate status of cognitive and brain aging in persons with chronic epilepsy but to identify cumulative risk factor exposure in younger years and determine the prognostic significance of this exposure to adverse cognitive outcomes as has been done in the general aging literature. The outcomes of such research would offer the opportunity to alter the trajectory of cognitive function in aging and elder years. While comorbidity studies raise the possibility of an association between chronic epilepsy and adverse cognitive outcomes, issues of causality need to be addressed by prospective investigations.

Why is it critical to characterize the pattern of cognitive and brain aging in elder persons with chronic epilepsy?

The expected increase in age-related cognitive disabilities including AD and associated disorders will exert a significant impact on the health and social well-being of this country. These projections and their fiscal and social implications have led multiple federal and private agencies to conduct clinical and research initiatives to promote cognitive and brain health in aging populations. Examples include the NIA/NINDS/NIMH Cognitive and Emotional Health Project: The Healthy Brain (; the CDC Healthy Brain Initiative: A National Public Health Road Map to Maintaining Cognitive Health (; and the Maintain Your Brain initiative of the Alzheimer’s Association ( These initiatives have yet to be recognized or embraced by the epilepsy community but they provide a template for clinical and research action for the future as well as an opportunity for collaborative research efforts.

Interestingly, it seems that more attention and concern was paid to the relationship between chronic epilepsy and dementia in the older literature (c.f., Friedlander (2001, pages 217-220). However, much of this work derived from special centers where patients with chronic, severe, and incapacitating epilepsy were cared for, with older and less precise characterizations of dementia and cognitive decline. Factors reported to be predictive of dementia included early-onset, poor seizure control, and long duration of epilepsy. Greater attention to the cognitive and brain health of aging and elder persons with chronic epilepsy would seem important, and natural partners in these research endeavors would be colleagues from the fields of aging and dementia. Finally, important related concerns and areas of research include the differential adverse cognitive outcomes (if any) associated with standard treatments such as AEDs and epilepsy surgery including anterior temporal lobectomy in elder persons with epilepsy, as well as the ultimate cognitive outcomes of persons who underwent anterior temporal lobectomy with hippocampectomy and are now approaching their elder years.


Evidence has been assembled to suggest that chronic epilepsy may be associated with significant abnormalities in cognition, brain structure, and psychiatric health that may progress by middle age in some patients, changes that are weakly predicted by traditional epilepsy factors. Additional evidence includes upregulated amyloid precursor protein, increased rates of senile plaque deposition and other neuropathologies, direct but limited evidence of particularly impaired mentation/dementia screening in elders with chronic epilepsy, and association of dementia with established epilepsy in medical record linkage studies. Prospective population-based research has identified numerous risk factors for abnormal cognitive aging and dementia in the general population, including vascular, inflammatory, and lifestyle factors, many of which we have shown to be overrepresented in epilepsy, but not examined in relationship to cognitive and brain aging in epilepsy. These are important oversights given the epidemiological evidence that risk exposure and cognitive abnormalities in midlife represent critical predictors of eventual abnormal cognitive and brain aging. If these factors exert comparable effects in people with chronic epilepsy, the management of epilepsy must be expanded to aggressively address critical risk factors in order to protect and promote cognitive and brain health. Identification of salient modifiable risk factors would open the opportunity to address these factors in order to improve both short-term and long-term cognitive and brain health.


The study was supported by NIH 2RO1 37738 and RO1 44351.


Disclosure of conflict of interest: There are no financial or other conflicts of interest related to the study. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines


  • Aldenkamp A, Arends J. The relative influence of epileptic EEG discharges, short nonconvulsive seizures, and type of epilepsy on cognitive function. Epilepsia. 2004;45:54–63. [PubMed]
  • Alessio A, Kobayashi E, Damasceno BP, Lopes-Cendes I, Cendes F. Evidence of memory impairment in asymptomatic individuals with hippocampal atrophy. Epilepsy Behav. 2004;5:981–987. [PubMed]
  • Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y. Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia. 2006;47:867–872. [PubMed]
  • Annegers JF, Hauser WA, Shirts SB. Heart disease mortality and morbidity in patients with epilepsy. Epilepsia. 1984;25:699–704. [PubMed]
  • Apeland T, Mansoor MA, Strandjord RE, Kristensen O. Homocysteine concentrations and methionine loading in patients on antiepileptic drugs. Acta Neurol Scand. 2000;101:217–223. [PubMed]
  • Apeland T, Mansoor MA, Strandjord RE. Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res. 2001a;47:27–35. [PubMed]
  • Apeland T, Mansoor MA, Strandjord RE, Vefring H, Kristensen O. Folate, homocysteine and methionine loading in patients on carbamazepine. Acta Neurol Scand. 2001b;103:294–299. [PubMed]
  • Ardekani S, Kumar A, Bartzokis G, Sinha U. Exploratory voxel-based analysis of diffusion indices and hemispheric asymmetry in normal aging. Magn Reson Imaging. 2007;25:154–167. [PubMed]
  • Attilakos A, Papakonstantinou E, Schulpis K, Voudris K, Katsarou E, Mastroyianni S, Garoufi A. Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. Epilepsy Res. 2006;71:229–232. [PubMed]
  • Aynaci FM, Orhan F, Örem A, Yildirmis S, Gedik Y. Effect of Antiepileptic drugs on plasma lipoprotein (a) and other lipid levels in childhood. J Child Neurol. 2001;16:367–369. [PubMed]
  • Baxendale SA, van Paesschen W, Thompson PJ, Connelly A, Duncan JS, Harkness WF, Shorvon SD. The relationship between quantitative MRI and neuropsychological functioning in temporal lobe epilepsy. Epilepsia. 1998;39:158–166. [PubMed]
  • Berenson GS, Srinivasan SR, Bao W, Newman WP, 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650–1656. [PubMed]
  • Berenson GS. Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa Heart Study. Am J Cardiol. 2002;90:3L–7L. [PubMed]
  • Berenson GS, Srnivasan SR. Cardiovascular risk factors in youth with implications for aging: the Bogalusa Heart Study. Neurobiol Aging. 2005;26:303–307. [PubMed]
  • Bernasconi N, Duchesne S, Janke A, Lerch J, Collins DL, Bernasconi A. Whole-brain voxel-based statistical analysis of gray matter and white matter in temporal lobe epilepsy. Neuroimage. 2004;23:717–723. [PubMed]
  • Bjorholt PG, Nakken KO, Rohme K, Hansen H. Leisure time habits and physical fitness in adults with epilepsy. Epilepsia. 1990;31:83–87. [PubMed]
  • Blumcke I, Brockhaus A, Scheiwe C, Rollbrocker B, Wolf HK, Elger CE, Wiestler OD. The apolipoprotein E epsilon4 allele is not associated with early onset temporal lobe epilepsy. Neuroreport. 1997;8:1235–1237. [PubMed]
  • Bonilha L, Rorden C, Appenzeller S, Coan AC, Cendes F, Li LM. Gray matter atrophy associated with duration of temporal lobe epilepsy. Neuroimage. 2006;32:1070–1079. [PubMed]
  • Bonilha L, Alessio A, Rorden C, Baylis G, Damasceno BP, Min LL, Cendes F. Extrahippocampal gray matter atrophy and memory impairment in patients with medial temporal lobe epilepsy. Hum Brain Mapping. In press. [PubMed]
  • Brämswig S, Sudhop T, Luers C, von Bergmann K, Berthold HK. Lipoprotein(a) concentration increases during treatment with carbamazepine. Epilepsia. 2003;44:457–460. [PubMed]
  • Breteler MM, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, EURODEM Risk Factors Research Group Medical history and the risk of Alzheimer’s disease: a collaborative re-analysis of case-control studies. Int J Epidemiol. 1991;20(Suppl 2):S36–S42. [PubMed]
  • Breteler MM, de Groot RR, van Romunde LK, Hofman A. Risk of dementia in patients with Parkinson’s disease, epilepsy, and severe head trauma: a register-based follow-up study. Am J Epidemiol. 1995;142:1300–1305. [PubMed]
  • Briellmann RS, Torn-Broers Y, Busuttil BE, Major BJ, Kalnins RM, Olsen M, Jackson GD, Frauman AG, Berkovic SF. APOE epsilon4 genotype is associated with an earlier onset of chronic temporal lobe epilepsy. Neurology. 2000;55:435–437. [PubMed]
  • Busch RM, Lineweaver TT, Naugle RI, Kim KH, Gong Y, Tilelli CQ, Prayson RA, Bingaman W, Najm IM, Diaz-Arrastia R. APOE-epsilon4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy. Neurology. 2007;68:409–414. [PubMed]
  • Castro-Gago M, Novo-Rodriguez MI, Blanco-Barca MO, Urisarri-Ruiz de Cortazar A, Rodriguez-Garcia J, Rodriguez-Segade S, Eiris-Punal J. Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital. J Child Neurol. 2006;21:48–53. [PubMed]
  • Cavalleri GL, Lynch JM, Depondt C, Burley MW, Wood NW, Sisodiya SM, Goldstein DB. Failure to replicate previously reported genetic associations with sporadic temporal lobe epilepsy: where to from here? Brain. 2005;128:1832–1840. [PubMed]
  • Chyou PH, White LR, Yano K, Sharp DS, Burchfiel CM, Chen R, Rodriguez BL, Curb JD. Pulmonary function measures as predictors and correlates of cognitive functioning in later life. Am J Epidemiol. 1996;143:750–756. [PubMed]
  • Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149–1155. [PubMed]
  • Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55:1449–1455. [PubMed]
  • Cloyd J, Hauser W, Towne A, Ramsay R, Mattson R, Gilliam F, Walczak T. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res. 2006;68(Suppl 1):S39–S48. [PubMed]
  • Collins NS, Shapiro RA, Ramsay RE. Elders with epilepsy. Med Clin North Am. 2006;90:945–966. [PubMed]
  • Cournot M, Marquie JC, Ansiau D, Martinaud C, Fonds H, Ferrieres J, Ruidavets JB. Relation between body mass index and cognitive function in healthy middle-aged men and women. Neurology. 2006;67:1208–1214. [PubMed]
  • de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke. 2002;33:1152–1162. [PubMed]
  • de la Torre JC. Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3:184–190. [PubMed]
  • de la Torre JC. Is Alzheimer’s disease preceded by neurodegeneration or cerebral hypoperfusion? Ann Neurol. 2005;57:783–784. [PubMed]
  • De Santi S, de Leon MJ, Convit A, Tarshish C, Rusinek H, Tsui WH, Sinaiko E, Wang GJ, Bartlet E, Volkow N. Age-related changes in brain: II. Positron emission tomography of frontal and temporal lobe glucose metabolism in normal subjects. Psychiatr Q. 1995;66:357–370. [PubMed]
  • Diaz-Arrastia R, Gong Y, Fair S, Scott KD, Garcia MC, Carlile MC, Agostini MA, Van Ness PC. Increased risk of late posttraumatic seizures associated with inheritance of APOE epsilon4 allele. Arch Neurol. 2003;60:818–822. [PubMed]
  • Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology. 2005;64:1371–1377. [PubMed]
  • Dixon RA, Backman L, Nilsson L, editors. New frontiers in cognitive aging. Oxford University Press; New York: 2004.
  • Dodrill CB. Neuropsychological effects of seizures. Epilepsy Behav. 2004;5(Suppl 1):S21–S24. [PubMed]
  • Dufouil C, Alperovitch A, Ducros V, Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol. 2003;53:214–221. [PubMed]
  • Duncan JS. Neuroimaging methods to evaluate the etiology and consequences of epilepsy. Epilepsy Res. 2002;50:131–140. [PubMed]
  • Eikelboom JW, Lonn E, Genest J, Jr., Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363–375. [PubMed]
  • Elger CE, Helmstaedter C, Kurthen M. Chronic epilepsy and cognition. Lancet Neurol. 2004;3:663–672. [PubMed]
  • Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol. 2004;61:668–672. [PubMed]
  • Fewlass DC, Noboa K, Pi-Sunyer FX, Johnston JM, Yan SD, Tezapsidis N. Obesity-related leptin regulates Alzheimer’s Abeta. FASEB J. 2004;18:1870–1878. [PubMed]
  • Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3:343–353. [PubMed]
  • Friedlander WJ. The modern history of epilepsy. The beginning, 1865-1914. Greenwood Press; London: 2001.
  • Gaitatzis A, Carroll K, Majeed A,JWS. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia. 2004;45:1613–1622. [PubMed]
  • Gambardella A, Aguglia U, Cittadella R, Romeo N, Sibilia G, LePiane E, Messina D, Manna I, Oliveri RL, Zappia M, Quattrone A. Apolipoprotein E polymorphisms and the risk of nonlesional temporal lobe epilepsy. Epilepsia. 1999;40:1804–1807. [PubMed]
  • Gambardella A, Aguglia U, Chifari R, Labate A, Manna I, Serra P, Romeo N, Sibilia G, Lepiane E, Russa AL, Ventura P, Cittadella R, Sasanelli F, Colosimo E, Leggio U, Zappia M, Quattrone A. APOE epsilon4 allele and disease duration affect verbal learning in mild temporal lobe epilepsy. Epilepsia. 2005;46:110–117. [PubMed]
  • Gouras GK, Relkin NR, Sweeney D, Munoz DG, Mackenzie IR, Gandy S. Increased apolipoprotein E epsilon4 in epilepsy with senile plaques. Ann Neurol. 1997;41:402–404. [PubMed]
  • Griffith HR, Martin RC, Bambara JK, Faught E, Vogtle LK, Marson DC. Cognitive functioning over 3 years in community dwelling older adults with chronic partial epilepsy. Epilepsy Res. 2007;74:91–96. [PubMed]
  • Griffith HR, Martin RC, Bambara JK, Marson DC, Faught E. Older adults with epilepsy demonstrate cognitive impairments compared with patients with amnestic mild cognitive impairment. Epilepsy Behav. 2006;8:161–168. [PubMed]
  • Greenwood CE, Winocur G. High-fat diets, insulin resistance and declining cognitive function. Neurobiol Aging. 2005;26(Suppl 1):42–45. [PubMed]
  • Gustafson D. Adiposity indices and dementia. Lancet Neurol. 2006;5:713–720. [PubMed]
  • Hamed SA, Nabeshima T. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. J Pharmacol Sci. 2005;98:340–353. [PubMed]
  • Hamed SA, Hamed EA, Hamdy R, Nabeshima T. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res. 2007;74:183–192. [PubMed]
  • Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999;354:407–413. [PubMed]
  • Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer’s disease. Neurology. 1986;36:1226–1230. [PubMed]
  • Helmstaedter C, Elger CE. The phantom of progressive dementia in epilepsy. Lancet. 1999;354:2133–2134. [PubMed]
  • Helmstaedter C, Kurthen M, Lux S, Reuber M, Elger CE. Chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy. Ann Neurol. 2003;54:425–432. [PubMed]
  • Hermann B, Hansen R, Seidenberg M, Magnotta V, O’Leary D. Neurodevelopmental vulnerability of the corpus callosum to childhood onset localization-related epilepsy. Neuroimage. 2003;18:284–292. [PubMed]
  • Hermann B, Seidenberg M, Sears L, Hansen R, Bayless K, Rutecki P, Dow C. Cerebellar atrophy in temporal lobe epilepsy affects procedural memory. Neurology. 2004;63:2129–2131. [PubMed]
  • Hermann BP, Seidenberg M, Dow C, Jones J, Rutecki P, Bhattacharya A, Bell B. Cognitive prognosis in chronic temporal lobe epilepsy. Ann Neurol. 2006;60:80–87. [PubMed]
  • Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA. Dementia and adult-onset unprovoked seizures. Neurology. 1996;46:727–730. [PubMed]
  • Isojarvi JI, Rattya J, Myllyla VV, Knip M, Koivunen R, Pakarinen AJ, Tekay A, Tapanainen JS. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol. 1998;43:446–451. [PubMed]
  • Jacoby A, Snape D, Baker GA. Epilepsy and social identity: the stigma of a chronic neurological disorder. Lancet Neurol. 2005;4:171–178. [PubMed]
  • Jalava M, Sillanpää M. Physical activity, health-related fitness, and health experience in adults with childhood-onset epilepsy: a controlled study. Epilepsia. 1997;38:424–429. [PubMed]
  • Jefferson AL, Massaro JM, Wolf PA, Seshadri S, Au R, Vasan RS, Larson MG, Meigs JB, Keaney JF, Jr, Lipinska I, Kathiresan S, Benjamin EJ, DeCarli C. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology. 2007;68:1032–1038. [PMC free article] [PubMed]
  • Jokeit H, Ebner A. Long term effects of refractory temporal lobe epilepsy on cognitive abilities: a cross sectional study. J Neurol Neurosurg Psychiatry. 1999;67:44–50. [PMC free article] [PubMed]
  • Jones JE, Hermann BP, Barry JJ, Gilliam F, Kanner AM, Meador KJ. Clinical assessment of Axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci. 2005;17:172–179. [PubMed]
  • Jones JE, Bell B, Fine J, Rutecki P, Seidenberg M, Hermann B. A controlled prospective investigation of psychiatric comorbidity in temporal lobe epilepsy. Epilepsia. In press. [PubMed]
  • Jones-Gotman M. Clinical neuropsychology and neocortical epilepsies. Adv Neurol. 2000;84:457–462. [PubMed]
  • Karabiber H, Sonmezgoz E, Ozerol E, Yakinci C, Otlu B, Yologlu S. Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev. 2003;25:113–115. [PubMed]
  • Kawas CH, Corrada MM, Brookmeyer R, Morrison A, Resnick SM, Zonderman AB, Arenberg D. Visual memory predicts Alzheimer’s disease more than a decade before diagnosis. Neurology. 2003;60:1089–1093. [PubMed]
  • Keller SS, Wieshmann UC, Mackay CE, Denby CE, Webb J, Roberts N. Voxel based morphometry of grey matter abnormalities in patients with medically intractable temporal lobe epilepsy: effects of side of seizure onset and epilepsy duration. J Neurol Neurosurg Psychiatry. 2002;73:648–655. [PMC free article] [PubMed]
  • Kilpatrick ES, Jagger CE, Spooner RJ, Brodie MJ. Apolipoprotein E and epilepsy. Ann Clin Biochem. 1996;33(Pt 2):146–147. [PubMed]
  • Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology. 2001a;56:1683–1689. [PubMed]
  • Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 2001b;322:1447–1451. [PMC free article] [PubMed]
  • Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149–155. [PubMed]
  • Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005;62:1556–1560. [PubMed]
  • Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, McGovern P, Folsom AR. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56:42–48. [PubMed]
  • Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005;4:371–380. [PubMed]
  • Laitinen MH, Ngandu T, Rovio S, Helkala EL, Uusitalo U, Viitanen M, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M. Fat intake at midlife and risk of dementia and Alzheimer’s disease: a population-based study. Dement Geriatr Cogn Disord. 2006;22:99–107. [PubMed]
  • Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49–55. [PubMed]
  • Lehtimaki KA, Keranen T, Huhtala H, Hurme M, Ollikainen J, Honkaniemi J, Palmio J, Peltola J. Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration. J Neuroimmunol. 2004;152:121–125. [PubMed]
  • Lin JJ, Salamon N, Lee AD, Dutton RA, Geaga JA, Hayashi KM, Luders E, Toga AW, Engel J, Jr, Thompson PM. Reduced neocortical thickness and complexity mapped in mesial temporal lobe epilepsy with hippocampal sclerosis. Cereb Cortex. 2007;17:2007–2018. [PubMed]
  • Liu RS, Lemieux L, Bell GS, Bartlett PA, Sander JW, Sisodiya SM, Shorvon SD, Duncan JS. A longitudinal quantitative MRI study of community-based patients with chronic epilepsy and newly diagnosed seizures: methodology and preliminary findings. Neuroimage. 2001;14:231–243. [PubMed]
  • Liu RS, Lemieux L, Bell GS, Hammers A, Sisodiya SM, Bartlett PA, Shorvon SD, Sander JW, Duncan JS. Progressive neocortical damage in epilepsy. Ann Neurol. 2003;53:312–324. [PubMed]
  • Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology. 2004;62:1972–1976. [PubMed]
  • Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, Bauer G, Lechleitner M. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol. 2004;55:729–732. [PubMed]
  • Mackenzie IR, Miller LA. Senile plaques in temporal lobe epilepsy. Acta Neuropathol (Berl) 1994;87:504–510. [PubMed]
  • McCaddon A, Hudson P, Davies G, Hughes A, Williams JH, Wilkinson C. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord. 2001;12:309–313. [PubMed]
  • McMillan AB, Hermann BP, Johnson SC, Hansen RR, Seidenberg M, Meyerand ME. Voxel-based morphometry of unilateral temporal lobe epilepsy reveals abnormalities in cerebral white matter. Neuroimage. 2004;23:167–174. [PubMed]
  • Malloy P, Correia S, Stebbins G, Laidlaw DH. Neuroimaging of white matter in aging and dementia. Clin Neuropsychol. 2007;21:73–109. [PubMed]
  • Martin RC, Hugg JW, Roth DL, Bilir E, Gilliam FG, Faught E, Kuzniecky RI. MRI extrahippocampal volumes and visual memory: correlations independent of MRI hippocampal volumes in temporal lobe epilepsy patients. J Int Neuropsychol Soc. 1999;6:540–548. [PubMed]
  • Martin RC, Griffith HR, Faught E, Gilliam F, Mackey M, Vogtle L. Cognitive functioning in community dwelling older adults with chronic partial epilepsy. Epilepsia. 2005;46:298–303. [PubMed]
  • Nakken KO. Physical exercise in outpatients with epilepsy. Epilepsia. 1999;40:643–651. [PubMed]
  • Ono H, Sakamoto A, Eguchi T, Fujita N, Nomura S, Ueda H, Sakura N, Ueda K. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Metabolism. 1997;46:959–962. [PubMed]
  • Oyegbile T, Hansen R, Magnotta V, O’Leary D, Bell B, Seidenberg M, Hermann BP. Quantitative measurement of cortical surface features in localization-related temporal lobe epilepsy. Neuropsychology. 2004;18:729–737. [PubMed]
  • Pantano P, Baron JC, Lebrun-Grandie P, Duquesnoy N, Bousser MG, Comar D. Regional cerebral blood flow and oxygen consumption in human aging. Stroke. 1984;15:635–641. [PubMed]
  • Panza F, D’Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, Capurso A, Solfrizzi V. Lipid metabolism in cognitive decline and dementia. Brain Res Brain Res Rev. 2006;51:275–292. [PubMed]
  • Pegna AJ, Caldara-Schnetzer AS, Perrig SH, Lazeyras F, Khateb A, Mayer E, Landis T, Seeck M. Is the right amygdala involved in visuospatial memory? Evidence from MRI volumetric measures. Eur Neurol. 2002;47:148–155. [PubMed]
  • Peltola J, Laaksonen J, Haapala AM, Hurme M, Rainesalo S, Keranen T. Indicators of inflammation after recent tonic-clonic epileptic seizures correlate with plasma interleukin-6 levels. Seizure. 2002;11:44–46. [PubMed]
  • Persson J, Nyberg L. Altered brain activity in healthy seniors: what does it mean? Prog Brain Res. 2006;157:45–56. [PubMed]
  • Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging. 2000;21:57–62. [PubMed]
  • Piazzini A, Canevini MP, Turner K, Chifari R, Canger R, Canevini MP. Elderly people and epilepsy: cognitive function. Epilepsia. 2006 [PubMed]
  • Pitkanen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol. 2002;1:173–181. [PubMed]
  • Pulsipher D, Seidenberg M, Morton J, Geary E, Parrish J, Hermann B, et al. MRI volume loss in subcortical structures in unilateral temporal lobe epilepsy. Epilepsy Behav. In press. [PMC free article] [PubMed]
  • Pylvanen V, Knip M, Pakarinen AJ, Turkka J, Kotila M, Rattya J, Myllyla VV, Isojarvi JI. Fasting serum insulin and lipid levels in men with epilepsy. Neurology. 2003;60:571–574. [PubMed]
  • Radhakrishnan A, Radhakrishnan K, Radhakrishnan VV, Mary PR, Kesavadas C, Alexander A, Sarma PS. Corpora amylacea in mesial temporal lobe epilepsy: clinico-pathological correlations. Epilepsy Res. 2007;74:81–90. [PubMed]
  • Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GD, Fowkes FG. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J Am Geriatr Soc. 2007;55:700–707. [PubMed]
  • Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr. 2005;82:636–643. [PubMed]
  • Raz N, Rodrigue KM, Haacke EM. Brain aging and its modifiers: insights from in vivo neuromorphometry and susceptibility weighted imaging. Ann NY Acad Sci. 2007;1097:84–93. [PMC free article] [PubMed]
  • Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, Tverdal A, Tell GS, Nygard O, Vollset SE. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006;136:1731S–1740S. [PubMed]
  • Romanelli MF, Morris JC, Ashkin K, Coben LA. Advanced Alzheimer’s disease is a risk factor for late-onset seizures. Arch Neurol. 1990;47:847–850. [PubMed]
  • Rovio S, Kareholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J, Soininen H, Nissinen A, Kivipelto M. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol. 2005;4:705–711. [PubMed]
  • Sandok EK, O’Brien TJ, Jack CR, So EL. Significance of cerebellar atrophy in intractable temporal lobe epilepsy: a quantitative MRI study. Epilepsia. 2000;41:1315–1320. [PubMed]
  • Sawrie SM, Martin RC, Knowlton R, Faught E, Gilliam F, Kuzniecky R. Relationships among hippocampal volumetry, proton magnetic resonance spectroscopy, and verbal memory in temporal lobe epilepsy. Epilepsia. 2001;42:1403–1407. [PubMed]
  • Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002;52:168–174. [PubMed]
  • Schwaninger M, Ringleb P, Winter R, Kohl B, Fiehn W, Rieser PA, Walter-Sack I. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia. 1999;40:345–350. [PubMed]
  • Schwaninger M, Ringleb P, Annecke A, Winter R, Kohl B, Werle E, Fiehn W, Rieser PA, Walter-Sack I. Elevated plasma concentrations of lipoprotein(a) in medicated epileptic patients. J Neurol. 2000;247:687–690. [PubMed]
  • Seidenberg M, Pulsipher DT, Hermann BP. Cognitive progression in epilepsy. Neuropsychol Rev. In Press. [PubMed]
  • Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002;346:476–483. [PubMed]
  • Sheng JG, Boop FA, Mrak RE, Griffin WS. Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1 alpha immunoreactivity. J Neurochem. 1994;63:1872–1879. [PMC free article] [PubMed]
  • Sheth RD. Metabolic concerns associated with antiepileptic medications. Neurology. 2004;63:S24–S29. [PubMed]
  • Sisodiya SM, Moran N, Free SL, Kitchen ND, Stevens JM, Harkness WF, Fish DR, Shorvon SD. Correlation of widespread preoperative magnetic resonance imaging changes with unsuccessful surgery for hippocampal sclerosis. Ann Neurol. 1997;41:490–496. [PubMed]
  • Solfrizzi V, D’Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, Capurso SA, Pietrarossa G, Santamato V, Capurso A, Panza F. Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta. 2006;364:91–112. [PubMed]
  • Sonmez FM, Demir E, Orem A, Yildirmis S, Orhan F, Aslan A, Topbas M. Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol. 2006;21:70–74. [PubMed]
  • Sparks DL, Scheff SW, Hunsaker JC, 3rd, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126:88–94. [PubMed]
  • Sporis D, Sertic J, Henigsberg N, Mahovic D, Bogdanovic N, Babic T. Association of refractory complex partial seizures with a polymorphism of APOE genotype. J Cell Mol Med. 2005;9:698–703. [PubMed]
  • Steinhoff BJ, Neusüss K, Thegeder H, Reimers CD. Leisure time activity and physical fitness in patients with epilepsy. Epilepsia. 1996;37:1221–1227. [PubMed]
  • Swinkels WA, Kuyk J, van Dyck R, Spinhoven P. Psychiatric comorbidity in epilepsy. Epilepsy Behav. 2005;7:37–50. [PubMed]
  • Tamura T, Aiso K, Johnston KE, Black L, Faught E. Homocysteine, folate, vitamin B-12 and vitamin B-6 in patients receiving antiepileptic drug monotherapy. Epilepsy Res. 2000;40:7–15. [PubMed]
  • Tellez-Zenteno JF, Matijevic S, Wiebe S. Somatic comorbidity of epilepsy in the general population in Canada. Epilepsia. 2005;46:1955–1962. [PubMed]
  • Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. In press. [PubMed]
  • Teunissen CE, van Boxtel MP, Bosma H, Bosmans E, Delanghe J, De Bruijn C, Wauters A, Maes M, Jolles J, Steinbusch HW, de Vente J. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol. 2003;134:142–150. [PubMed]
  • Tilvis RS, Kahonen-Vare MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci. 2004;59:268–274. [PubMed]
  • Trenerry MR, Jack CR, Jr, Ivnik RJ, Sharbrough FW, Cascino GD, Hirschorn KA, Marsh WR, Kelly PJ, Meyer FB. MRI hippocampal volumes and memory function before and after temporal lobectomy. Neurology. 1995;45:396. [PubMed]
  • Troen A, Rosenberg I. Homocysteine and cognitive function. Semin Vasc Med. 2005;5:209–214. [PubMed]
  • Tümer L, Serdaroğlu A, Hasanoğlu A, Biberoğlu G, Aksoy E. Plasma homocysteine and lipoprotein (a) levels as risk factors for atherosclerotic vascular disease in epileptic children taking anticonvulsants. Acta Paediatr. 2002;91:923–926. [PubMed]
  • Tyas SL, White LR, Petrovitch H, Webster Ross G, Foley DJ, Heimovitz HK, Launer LJ. Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. Neurobiol Aging. 2003;24:589–596. [PubMed]
  • van Oijen M, Jan de Jong F, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Ann Neurol. 2007;61:403–410. [PubMed]
  • Verrotti A, Pascarella R, Trotta D, Giuva T, Morgese G, Chiarelli F. Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res. 2000;41:253–257. [PubMed]
  • Verrotti A, Basciani F, Trotta D, Greco R, Morgese G, Chiarelli F. Effect of anticonvulsant drugs on interleukins-1, -2 and -6 and monocyte chemoattractant protein-1. Clin Exp Med. 2001;1:133–136. [PubMed]
  • Vezzani A. Inflammation and epilepsy. Epilepsy Curr. 2005;5:1–6. [PMC free article] [PubMed]
  • Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia. 2005;46:1724–1743. [PubMed]
  • Voudris KA, Attilakos A, Katsarou E, Drakatos A, Dimou S, Mastroyianni S, Skardoutsou A, Prassouli A, Garoufi A. Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res. 2006;70:211–217. [PubMed]
  • Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202. [PMC free article] [PubMed]
  • Watson GS, Craft S. Insulin resistance, inflammation, and cognition in Alzheimer’s disease: lessons for multiple sclerosis. J Neurol Sci. 2006;245:21–33. [PubMed]
  • Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology. 2002;59:371–378. [PubMed]
  • Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277–281. [PubMed]
  • Wong J, Wirrell E. Physical activity in children/teens with epilepsy compared with that in their siblings without epilepsy. Epilepsia. 2006;47:631–639. [PubMed]
  • Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003;61:76–80. [PubMed]
  • Yeni SN, Ozkara C, Buyru N, Baykara O, Hanoglu L, Karaagac N, Ozyurt E, Uzan M. Association between APOE polymorphisms and mesial temporal lobe epilepsy with hippocampal sclerosis. Eur J Neurol. 2005;12:103–107. [PubMed]
  • Yoo JH, Hong SB. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. Metabolism. 1999;48:1047–1051. [PubMed]
  • Yu A, Li K, Li L, Shan B, Wang Y, Xue S. Whole-brain voxel-based morphometry of white matter in medial temporal lobe epilepsy. Eur J Radiol. In press. [PubMed]
  • Zonderman AB, Giambra LM, Arenberg D, Resnick SM, Costa PT, Jr, Kawas CH. Changes in immediate visual memory predict cognitive impairment. Arch Clin Neuropsychol. 1995;10:111–123. [PubMed]